Hikma Gets FTC Nod For Custopharm Deal – But With Strings Attached
Acquisition Moves Closer To Completion, But Combining Firms Must Lose A Product
Hikma has moved closer to completing a deal worth more than $400m to acquire Custopharm, which promises to bolster its US injectables business. However, the FTC’s approval of the transaction comes with conditions.
